share_log

Short Interest in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Drops By 46.0%

Short Interest in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Drops By 46.0%

对Comera生命科学控股公司(纳斯达克股票代码:CMRAW)的空头利率下降了46.0%
Defense World ·  2022/12/30 18:11

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 8,100 shares, a drop of 46.0% from the November 30th total of 15,000 shares. Based on an average daily volume of 15,600 shares, the days-to-cover ratio is presently 0.5 days.

Comera Life Sciences Holdings, Inc.(纳斯达克股票代码:CMRAW — 获取评级)是12月空头利率大幅下降的目标。截至12月15日,空头利率共计8,100股,较11月30日的15,000股总额下降了46.0%。根据15,600股的平均每日成交量,目前的天数与覆盖率为0.5天。

Comera Life Sciences Price Performance

Comera 生命科学价格表现

CMRAW stock opened at $0.05 on Friday. The stock's 50 day moving average is $0.05. Comera Life Sciences has a 52 week low of $0.03 and a 52 week high of $0.70.

周五,CMRAW股票开盘价为0.05美元。该股的50天移动平均线为0.05美元。Comera Life Sciences创下52周低点0.03美元,52周高点为0.70美元。

Get
获取
Comera Life Sciences
科梅拉生命科学
alerts:
警报:

Institutional Trading of Comera Life Sciences

Comera 生命科学的机构交易

A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new stake in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 202,000 shares of the company's stock, valued at approximately $29,000.

一家对冲基金最近购买了Comera Life Sciences股票的新股份。根据沃伯格资产管理有限责任公司向美国证券交易委员会(SEC)提交的最新文件,该公司在第二季度收购了Comera Life Sciences Holdings, Inc.(纳斯达克股票代码:CMRAW — 获取评级)的新股份。该基金购买了该公司20.2万股股票,价值约29,000美元。

About Comera Life Sciences

关于 Comera 生命科学

(Get Rating)
(获取评分)

Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.

Comera Life Sciences Holdings, Inc是一家临床前阶段的生命科学公司,该公司开发了内部专有疗法产品组合,其中包括其专有配方平台SqorE。其SqorE平台旨在实现静脉注射(IV)生物制剂转换为皮下(SQ)版本。

Read More

阅读更多

  • Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
  • Should You Warm up to Generac Stock for the Winter?
  • Is Kintara Therapeutics A Hidden Gem?
  • 3 High-Yield Dividend Stocks to Hold for the Long Haul
  • Cal-Maine Posts Record Quarter, Remain CALM Income Investors
  • Tesla Stock: What the Bulls and the Bears Are Getting Wrong
  • 免费获取 StockNews.com 关于 Comera Life Sciences(CMRAW)的研究报告
  • 你应该为冬天的 Generac Stock 做热身吗?
  • 金塔拉疗法是隐藏的宝石吗?
  • 3只高收益股息股票可供长期持有
  • 加州缅因州公布创纪录的季度业绩,收益投资者保持冷静
  • 特斯拉股票:多头和空头做错了什么

Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

接收《Comera生命科学日报》的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Comera Life Sciences及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发